688443 Chongqing Genrix Biopharmaceutical
- 26.36
- +0.60+2.33%
Chongqing Genrix Biopharmaceutical News
2024 Semi-Annual Report
2024 Semi-Annual Report Summary
Zhixiang Jintai (688443.SH) released its performance for the first half of the year, with a net loss of 0.362 billion yuan.
Zhixiang Jintai (688443.SH) released the 2024 interim report, with a revenue of 1...
Genrix Biopharmaceutical's Celecoxib Injection Gets Nod to Be Registered; Shares Drop 4%
The first approved product on the market, Zhixiang Jintai (688443.SH): Celgene's monoclonal antibody for the treatment of moderate to severe plaque psoriasis.
Zhixiang Jintai (688443.SH) announced today that the company has received the "Pharmaceuticals..." issued by the State Administration for Market Regulation.
Chongqing Genrix Biopharmaceutical (SHSE:688443) Is Using Debt Safely
Zhixiang Jintai (688443.SH): GR1802 Injection obtained the drug clinical trial approval notice for children and adolescents with atopic dermatitis.
On August 23, the company announced that it has received the Approval Notification for Drug Clinical Trial issued by the National Medical Products Administration. The company's clinical trial application for the indication of pediatric and adolescent atopic dermatitis for its investigational product GR1802 Injection has been approved. GR1802 Injection is a recombinant fully human anti-IL-4Rα monoclonal antibody developed by the company, which targets IL-4Rα. GR1802 Injection can specifically bind to the human IL-4Rα on the cell surface, block the binding of IL-4 and IL-13 to IL-4Rα, and inhibit downstream signal transduction pathways.
Zhixiang Jintai (688443.SH): GR2001 injection launched Phase III clinical trial.
On August 14th, Gelunhui reported that Zhixiang Jintai (688443.SH) had completed communication with the Center for Drug Evaluation of the National Medical Products Administration (CDE) EOP2 (Phase II clinical trial completed/Phase III clinical trial started) on the conduct of a randomized, double-blind, tetanus immunoglobulin-controlled, multicenter Phase III clinical trial of the efficacy and safety of the evaluation of muscle injection GR2001 injection in suspected tetanus exposed persons, and the company will formally launch the Phase III clinical trial.
Haitong Int'l: Immune therapy has a broad market space, and the clinical value of TCE dual-antibodies is prominent.
With the development and maturity of TCE dual antibody technology, more domestic enterprises will choose to layout TCE dual antibody in order to enter the race track of solid tumors and self-immunity areas. TCE dual antibody has the potential to become the next investment trend in the field of immunotherapy.
Zhixiang Jintai (688443.SH): GR1803 injection has been included in the list of breakthrough therapeutic varieties.
On August 12th, Gelun Hui announced that its product GR1803 injection has been included in the list of breakthrough therapeutic products by the Drug Evaluation Center of China's National Medical Products Administration and the publication has been completed. GR1803 injection is a bi-specific antibody drug independently developed by the company, targeting BCMA and CD3. Its registration classification is Class 1 biological product for therapeutic use. GR1803 injection is a bi-specific antibody molecule based on co-constructed light chains. Its structure is highly similar to that of normal monoclonal antibody molecules, which not only facilitates the development of its preparation process but also reduces the structural differences that may cause
Zhi Xiang Jintai (688443.SH): GR1802 injection starts phase III clinical trial for chronic sinusitis with nasal polyps indication.
On August 6th, Gelonghui reported that Zhixiang Jintai (688443.SH) announced the launch of a randomized, double-blind, placebo-controlled, multicenter phase III clinical trial to evaluate the effectiveness, safety and immunogenicity of GR1802 injection in patients with chronic sinusitis and nasal polyps. The company completed a meeting with the Center for Drug Evaluation (CDE) EOP2 (phase II clinical trial completion/phase III clinical trial initiation) of the State Administration for Drug Supervision and Administration for drug evaluation, and it will officially launch the phase III clinical trial. GR1802 injection is a recombinant human anti-IL- drug independently developed by the company.
Institutions Along With Private Equity Firms Who Hold Considerable Shares InChongqing Genrix Biopharmaceutical Co., Ltd. (SHSE:688443) Come Under Pressure; Lose 5.6% of Holdings Value
Zhixiang Jintai (688443.SH): the preventive tetanus drug "GR2001 injection" has been included in the list of breakthrough therapies.
Zhixiang Jintai (688443.SH) announced that the company's pharmaceutical, GR2001 injection, has been approved by the National Medical Products Administration of China.
Zhixiang Jintai (688443.SH): At the end of the term, Jiang Ren, the actual controller, increased the company's shares by about 31.22,200 yuan
Gelonghui, May 17, 丨 Zhixiang Jintai (688443.SH) announced that as of May 16, 2024, the actual controller, Mr. Jiang Rensheng, had increased his holdings of the company's 875,582 shares through centralized bidding through the Shanghai Stock Exchange trading system, accounting for about 0.24% of the company's total issued share capital. The total increase amount amount of about RMB 31.22,200 million has been reached, reaching the lower limit of the increase range of RMB 30 million. The period of this increase plan has expired and the implementation of the increase in holdings has been completed.
Is Chongqing Genrix Biopharmaceutical (SHSE:688443) Using Too Much Debt?
Zhixiang Jintai (688443.SH) reported first-quarter results with a net loss of 164 million yuan
Zhixiang Jintai (688443.SH) released its report for the first quarter of 2024, with revenue of 6,330.27...
Guoxin Securities: The pharmaceutical industry is entering an upward inflection point in the medium to long term, and focus on high growth targets in the quarterly report in the short term
The pharmaceutical industry currently has low growth, low profitability, undervaluation, and low transaction attention, and is entering a major layout range at an upward inflection point in the medium to long term.
Private Equity Firms in Chongqing Genrix Biopharmaceutical Co., Ltd. (SHSE:688443) Are Its Biggest Bettors, and Their Bets Paid off as Stock Gained 15% Last Week
Guoxin Securities: Focus on the immediate needs of medical care, focus on the high growth targets of the first quarter report
The pharmaceutical industry currently has low growth, low profitability, undervaluation, and low transaction attention, and is entering a major layout range at an upward inflection point in the medium to long term.
Chongqing Genrix Biopharmaceutical Co., Ltd.'s (SHSE:688443) Intrinsic Value Is Potentially 100% Above Its Share Price
Analysis
Price Target
No Data
